ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) does about 2.11M shares in volume on a normal day but saw 3441095 shares change hands in the recent trading day. The company now has a market cap of 90.61M USD. Its current market price is $1.98, marking an increase of 33.78% compared to the previous close of $1.48. The 52 week high reached by this stock is $2.01 whilst the lowest price level in 52 weeks is $0.27.
ImmunoPrecise Antibodies Ltd (IPA) has a 20-day trading average at $1.2260 and the current price is -1.49% off the 52-week high compared with 633.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.8132 and its 200-day simple moving average is $0.5475. If we look at the stock’s price movements over the week, volatility stands at 21.56%, which decreases to 18.78% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 73.08 to suggest the stock is overbought.
The consensus objective for the share price is $4.07, suggesting that the stock has a potential upside of 51.35% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 02, 2022 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $9.
The current price level is 61.50%, 143.48%, and 261.66% away from its SMA20, SMA50, and SMA200 respectively, with the IPA price moving below the 50-day SMA on current market day. ImmunoPrecise Antibodies Ltd (IPA) stock is up 21.47% over the week and 229.78% over the past month. Its price is 102.04% year-to-date and 380.93% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $6.4M, which analysts say will come at $25.43M for the current fiscal year and next year at $29M. In addition, estimates put the company’s current quarterly revenue at an average of $7.89M.
To reach the target analysts have set, the stock logically needs to grow 51.35 percent from here.
Outstanding shares total 45.77M with insiders holding 5.21% of the shares and institutional holders owning 8.59% of the company’s common stock. The company has a return on investment of -132.36% and return on equity of -121.65%. The beta has a value of 0.49. Price to book ratio is 5.22 and price to sales ratio is 5.20.
